Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.43 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | APAF1 | O14727 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL19878453 | 0.94 | TDP1 (0.51) | MEN1BLMKMT2ATDP1THRB | |
| Acetic Acid SCHEMBL19878290 | 0.89 | MEN1 (0.52) | MEN1BLMKMT2ATDP1THRB | |
| Acetic Acid SCHEMBL30378926 | 0.89 | MEN1 (0.52) | MEN1BLMKMT2ATDP1THRB | |
| SCHEMBL19878292 | 0.89 | MEN1 (0.46) | MEN1BLMKMT2ATDP1THRB | |
| Bromide SCHEMBL28991374 | 0.87 | TDP1 (0.37) | MEN1BLMKMT2ATDP1THRB | |
| Bromide SCHEMBL30378600 | 0.87 | TDP1 (0.37) | MEN1BLMKMT2ATDP1THRB | |
| Bromide SCHEMBL28730392 | 0.86 | TDP1 (0.47) | MEN1BLMKMT2ATDP1THRB | |
| SCHEMBL19878383 | 0.85 | MEN1 (0.54) | MEN1BLMKMT2ATDP1THRB | |
| Acetic Acid SCHEMBL19878400 | 0.83 | MEN1 (0.52) | MEN1BLMKMT2ATDP1THRB | |
| SCHEMBL19878401 | 0.83 | MEN1 (0.46) | MEN1BLMKMT2ATDP1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3500860-A1 | COMPOSITION AND METHODS FOR MEASURING ION CHANNEL ACTIVITY IN A CELL | Life Technologies Corporation (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20190187155-A1 | COMPOSITION AND METHODS FOR MEASURING ION CHANNEL ACTIVITY IN A CELL | Life Technologies Corporation | 2019-06-20 | — | — | US | disclosed |
| WO-2018035230-A1 | COMPOSITION AND METHODS FOR MEASURING ION CHANNEL ACTIVITY IN A CELL | Life Technologies Corporation (US) | 2018-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190187155-A1 | COMPOSITION AND METHODS FOR MEASURING ION CHANNEL ACTIVITY IN A CELL | TMCO1, TRPM5, CLIC1 | ACHE 527/4885MEN1 1477/4885BLM 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.